Burnham & Co LLC Buys Shares of 1,670 Thermo Fisher Scientific Inc. $TMO

Key Points

• Burnham & Co. acquired 1,670 Thermo Fisher shares worth approximately $837,000 during the second quarter. Institutional investors collectively own 89.23% of TMO.
• Thermo Fisher exceeded quarterly expectations, reporting $6.03 in EPS and $11.99 billion in revenue, with revenue up 10.5% year over year. Analysts maintain a “Moderate Buy” consensus rating and an average price target of $619.41.
• TMO recently traded near its 52-week high at $629.02 and pays a quarterly dividend of $0.47 per share, while company insiders have sold 63,493 shares worth approximately $37.7 million over the past 90 days.

Burnham & Co LLC acquired a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 1,670 shares of the medical research company's stock, valued at approximately $837,000.

Several other hedge funds and other institutional investors have also bought and sold shares of TMO. Elyxium Wealth LLC increased its stake in shares of Thermo Fisher Scientific by 1.9% during the fourth quarter. Elyxium Wealth LLC now owns 1,058 shares of the medical research company's stock valued at $613,000 after buying an additional 20 shares during the period. Revolve Wealth Partners LLC increased its position in Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after purchasing an additional 20 shares during the period. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. raised its holdings in Thermo Fisher Scientific by 0.7% in the 3rd quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. now owns 2,960 shares of the medical research company's stock worth $1,436,000 after purchasing an additional 20 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Thermo Fisher Scientific by 0.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,985 shares of the medical research company's stock worth $2,311,000 after purchasing an additional 22 shares during the period. Finally, Canandaigua National Trust Co of Florida boosted its stake in shares of Thermo Fisher Scientific by 3.0% during the 4th quarter. Canandaigua National Trust Co of Florida now owns 765 shares of the medical research company's stock valued at $443,000 after purchasing an additional 22 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on TMO. Royal Bank Of Canada boosted their price objective on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a "sector perform" rating in a research note on Friday, July 24th. Piper Sandler boosted their price target on Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a "neutral" rating in a research report on Monday, July 27th. Wall Street Zen upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Saturday, August 1st. Stifel Nicolaus set a $650.00 price objective on Thermo Fisher Scientific in a research note on Wednesday, August 5th. Finally, Wells Fargo & Company dropped their target price on Thermo Fisher Scientific from $675.00 to $615.00 and set an "overweight" rating on the stock in a report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $619.41.

Thermo Fisher Scientific Trading Up 0.2%

Thermo Fisher Scientific stock opened at $629.02 on Friday. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $643.99. The firm's 50 day moving average price is $542.53 and its 200-day moving average price is $509.70. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The stock has a market cap of $232.58 billion, a P/E ratio of 33.84, a PEG ratio of 2.56 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating analysts' consensus estimates of $5.71 by $0.32. The firm had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. Thermo Fisher Scientific's revenue for the quarter was up 10.5% compared to the same quarter last year. During the same period last year, the firm posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific's payout ratio is 10.11%.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $574.47, for a total value of $5,744,700.00. Following the completion of the sale, the chief executive officer directly owned 123,925 shares of the company's stock, valued at $71,191,194.75. The trade was a 7.47% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of the business's stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the sale, the chief accounting officer owned 2,966 shares of the company's stock, valued at $1,734,546.46. The trade was a 12.40% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 63,493 shares of company stock valued at $37,657,681. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source